
Bevacizumab Injection Industry Research Report 2025
Description
Summary
According to APO Research, the global Bevacizumab Injection market was valued at US$ million in 2024 and is anticipated to reach US$ million by 2031, witnessing a CAGR of xx% during the forecast period 2025-2031.
North American market for Bevacizumab Injection is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
Asia-Pacific market for Bevacizumab Injection is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
Europe market for Bevacizumab Injection is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
The major global manufacturers of Bevacizumab Injection include Biocon, Cadila Pharmaceuticals, Centus, Dr Reddy's, Genentech, Hetero Group, Samsung Bioepis, Amgen and Bayer, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Bevacizumab Injection, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Bevacizumab Injection.
The report will help the Bevacizumab Injection manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
The Bevacizumab Injection market size, estimations, and forecasts are provided in terms of sales volume (K Doses) and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Bevacizumab Injection market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided. For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
Key Companies & Market Share Insights
In this section, the readers will gain an understanding of the key players competing. This report has studied the key growth strategies, such as innovative trends and developments, intensification of product portfolio, mergers and acquisitions, collaborations, new product innovation, and geographical expansion, undertaken by these participants to maintain their presence. Apart from business strategies, the study includes current developments and key financials. The readers will also get access to the data related to global revenue, price, and sales by manufacturers for the period 2020-2025. This all-inclusive report will certainly serve the clients to stay updated and make effective decisions in their businesses.
Bevacizumab Injection Segment by Company
Biocon
Cadila Pharmaceuticals
Centus
Dr Reddy's
Genentech
Hetero Group
Samsung Bioepis
Amgen
Bayer
Pfizer
Eli Lilly
Roche
Mylan
Bevacizumab Injection Segment by Type
100mg
400mg
Bevacizumab Injection Segment by Application
Age-related macular degeneration (AMD)
Ovarian Cancer
Others
Bevacizumab Injection Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Bevacizumab Injection market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Bevacizumab Injection and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Bevacizumab Injection.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Detailed analysis of Bevacizumab Injection manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.
Chapter 5: Production/output, value of Bevacizumab Injection by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.
Chapter 6: Consumption of Bevacizumab Injection in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.
Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 11: The main points and conclusions of the report.
According to APO Research, the global Bevacizumab Injection market was valued at US$ million in 2024 and is anticipated to reach US$ million by 2031, witnessing a CAGR of xx% during the forecast period 2025-2031.
North American market for Bevacizumab Injection is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
Asia-Pacific market for Bevacizumab Injection is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
Europe market for Bevacizumab Injection is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
The major global manufacturers of Bevacizumab Injection include Biocon, Cadila Pharmaceuticals, Centus, Dr Reddy's, Genentech, Hetero Group, Samsung Bioepis, Amgen and Bayer, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Bevacizumab Injection, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Bevacizumab Injection.
The report will help the Bevacizumab Injection manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
The Bevacizumab Injection market size, estimations, and forecasts are provided in terms of sales volume (K Doses) and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Bevacizumab Injection market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided. For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
Key Companies & Market Share Insights
In this section, the readers will gain an understanding of the key players competing. This report has studied the key growth strategies, such as innovative trends and developments, intensification of product portfolio, mergers and acquisitions, collaborations, new product innovation, and geographical expansion, undertaken by these participants to maintain their presence. Apart from business strategies, the study includes current developments and key financials. The readers will also get access to the data related to global revenue, price, and sales by manufacturers for the period 2020-2025. This all-inclusive report will certainly serve the clients to stay updated and make effective decisions in their businesses.
Bevacizumab Injection Segment by Company
Biocon
Cadila Pharmaceuticals
Centus
Dr Reddy's
Genentech
Hetero Group
Samsung Bioepis
Amgen
Bayer
Pfizer
Eli Lilly
Roche
Mylan
Bevacizumab Injection Segment by Type
100mg
400mg
Bevacizumab Injection Segment by Application
Age-related macular degeneration (AMD)
Ovarian Cancer
Others
Bevacizumab Injection Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Bevacizumab Injection market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Bevacizumab Injection and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Bevacizumab Injection.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Detailed analysis of Bevacizumab Injection manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.
Chapter 5: Production/output, value of Bevacizumab Injection by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.
Chapter 6: Consumption of Bevacizumab Injection in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.
Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 11: The main points and conclusions of the report.
Table of Contents
128 Pages
- 1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
- 2 Market Overview
- 2.1 Product Definition
- 2.2 Global Market Growth Prospects
- 2.2.1 Global Bevacizumab Injection Market Size (2020-2031)
- 2.2.2 Global Bevacizumab Injection Sales (2020-2031)
- 2.2.3 Global Bevacizumab Injection Market Average Price (2020-2031)
- 2.3 Bevacizumab Injection by Type
- 2.3.1 Market Value Comparison by Type (2020 VS 2024 VS 2031) & (US$ Million)
- 2.3.2 100mg
- 2.3.3 400mg
- 2.4 Bevacizumab Injection by Application
- 2.4.1 Market Value Comparison by Application (2020 VS 2024 VS 2031)
- 2.4.2 Age-related macular degeneration (AMD)
- 2.4.3 Ovarian Cancer
- 2.4.4 Others
- 3 Market Competitive Landscape by Manufacturers
- 3.1 Global Bevacizumab Injection Market Competitive Situation by Manufacturers (2020 Versus 2024)
- 3.2 Global Bevacizumab Injection Sales (K Doses) of Manufacturers (2020-2025)
- 3.3 Global Bevacizumab Injection Revenue of Manufacturers (2020-2025)
- 3.4 Global Bevacizumab Injection Average Price by Manufacturers (2020-2025)
- 3.5 Global Bevacizumab Injection Industry Ranking, 2023 VS 2024 VS 2025
- 3.6 Global Manufacturers of Bevacizumab Injection, Manufacturing Sites & Headquarters
- 3.7 Global Manufacturers of Bevacizumab Injection, Product Type & Application
- 3.8 Global Manufacturers of Bevacizumab Injection, Established Date
- 3.9 Global Bevacizumab Injection Market CR5 and HHI
- 3.10 Global Manufacturers Mergers & Acquisition
- 4 Manufacturers Profiled
- 4.1 Biocon
- 4.1.1 Biocon Company Information
- 4.1.2 Biocon Business Overview
- 4.1.3 Biocon Bevacizumab Injection Sales, Revenue and Gross Margin (2020-2025)
- 4.1.4 Biocon Bevacizumab Injection Product Portfolio
- 4.1.5 Biocon Recent Developments
- 4.2 Cadila Pharmaceuticals
- 4.2.1 Cadila Pharmaceuticals Company Information
- 4.2.2 Cadila Pharmaceuticals Business Overview
- 4.2.3 Cadila Pharmaceuticals Bevacizumab Injection Sales, Revenue and Gross Margin (2020-2025)
- 4.2.4 Cadila Pharmaceuticals Bevacizumab Injection Product Portfolio
- 4.2.5 Cadila Pharmaceuticals Recent Developments
- 4.3 Centus
- 4.3.1 Centus Company Information
- 4.3.2 Centus Business Overview
- 4.3.3 Centus Bevacizumab Injection Sales, Revenue and Gross Margin (2020-2025)
- 4.3.4 Centus Bevacizumab Injection Product Portfolio
- 4.3.5 Centus Recent Developments
- 4.4 Dr Reddy's
- 4.4.1 Dr Reddy's Company Information
- 4.4.2 Dr Reddy's Business Overview
- 4.4.3 Dr Reddy's Bevacizumab Injection Sales, Revenue and Gross Margin (2020-2025)
- 4.4.4 Dr Reddy's Bevacizumab Injection Product Portfolio
- 4.4.5 Dr Reddy's Recent Developments
- 4.5 Genentech
- 4.5.1 Genentech Company Information
- 4.5.2 Genentech Business Overview
- 4.5.3 Genentech Bevacizumab Injection Sales, Revenue and Gross Margin (2020-2025)
- 4.5.4 Genentech Bevacizumab Injection Product Portfolio
- 4.5.5 Genentech Recent Developments
- 4.6 Hetero Group
- 4.6.1 Hetero Group Company Information
- 4.6.2 Hetero Group Business Overview
- 4.6.3 Hetero Group Bevacizumab Injection Sales, Revenue and Gross Margin (2020-2025)
- 4.6.4 Hetero Group Bevacizumab Injection Product Portfolio
- 4.6.5 Hetero Group Recent Developments
- 4.7 Samsung Bioepis
- 4.7.1 Samsung Bioepis Company Information
- 4.7.2 Samsung Bioepis Business Overview
- 4.7.3 Samsung Bioepis Bevacizumab Injection Sales, Revenue and Gross Margin (2020-2025)
- 4.7.4 Samsung Bioepis Bevacizumab Injection Product Portfolio
- 4.7.5 Samsung Bioepis Recent Developments
- 4.8 Amgen
- 4.8.1 Amgen Company Information
- 4.8.2 Amgen Business Overview
- 4.8.3 Amgen Bevacizumab Injection Sales, Revenue and Gross Margin (2020-2025)
- 4.8.4 Amgen Bevacizumab Injection Product Portfolio
- 4.8.5 Amgen Recent Developments
- 4.9 Bayer
- 4.9.1 Bayer Company Information
- 4.9.2 Bayer Business Overview
- 4.9.3 Bayer Bevacizumab Injection Sales, Revenue and Gross Margin (2020-2025)
- 4.9.4 Bayer Bevacizumab Injection Product Portfolio
- 4.9.5 Bayer Recent Developments
- 4.10 Pfizer
- 4.10.1 Pfizer Company Information
- 4.10.2 Pfizer Business Overview
- 4.10.3 Pfizer Bevacizumab Injection Sales, Revenue and Gross Margin (2020-2025)
- 4.10.4 Pfizer Bevacizumab Injection Product Portfolio
- 4.10.5 Pfizer Recent Developments
- 4.11 Eli Lilly
- 4.11.1 Eli Lilly Company Information
- 4.11.2 Eli Lilly Business Overview
- 4.11.3 Eli Lilly Bevacizumab Injection Sales, Revenue and Gross Margin (2020-2025)
- 4.11.4 Eli Lilly Bevacizumab Injection Product Portfolio
- 4.11.5 Eli Lilly Recent Developments
- 4.12 Roche
- 4.12.1 Roche Company Information
- 4.12.2 Roche Business Overview
- 4.12.3 Roche Bevacizumab Injection Sales, Revenue and Gross Margin (2020-2025)
- 4.12.4 Roche Bevacizumab Injection Product Portfolio
- 4.12.5 Roche Recent Developments
- 4.13 Mylan
- 4.13.1 Mylan Company Information
- 4.13.2 Mylan Business Overview
- 4.13.3 Mylan Bevacizumab Injection Sales, Revenue and Gross Margin (2020-2025)
- 4.13.4 Mylan Bevacizumab Injection Product Portfolio
- 4.13.5 Mylan Recent Developments
- 5 Global Bevacizumab Injection Market Scenario by Region
- 5.1 Global Bevacizumab Injection Market Size by Region: 2020 VS 2024 VS 2031
- 5.2 Global Bevacizumab Injection Sales by Region: 2020-2031
- 5.2.1 Global Bevacizumab Injection Sales by Region: 2020-2025
- 5.2.2 Global Bevacizumab Injection Sales by Region: 2026-2031
- 5.3 Global Bevacizumab Injection Revenue by Region: 2020-2031
- 5.3.1 Global Bevacizumab Injection Revenue by Region: 2020-2025
- 5.3.2 Global Bevacizumab Injection Revenue by Region: 2026-2031
- 5.4 North America Bevacizumab Injection Market Facts & Figures by Country
- 5.4.1 North America Bevacizumab Injection Market Size by Country: 2020 VS 2024 VS 2031
- 5.4.2 North America Bevacizumab Injection Sales by Country (2020-2031)
- 5.4.3 North America Bevacizumab Injection Revenue by Country (2020-2031)
- 5.4.4 United States
- 5.4.5 Canada
- 5.5 Europe Bevacizumab Injection Market Facts & Figures by Country
- 5.5.1 Europe Bevacizumab Injection Market Size by Country: 2020 VS 2024 VS 2031
- 5.5.2 Europe Bevacizumab Injection Sales by Country (2020-2031)
- 5.5.3 Europe Bevacizumab Injection Revenue by Country (2020-2031)
- 5.5.4 Germany
- 5.5.5 France
- 5.5.6 U.K.
- 5.5.7 Italy
- 5.5.8 Netherlands
- 5.6 Asia Pacific Bevacizumab Injection Market Facts & Figures by Country
- 5.6.1 Asia Pacific Bevacizumab Injection Market Size by Country: 2020 VS 2024 VS 2031
- 5.6.2 Asia Pacific Bevacizumab Injection Sales by Country (2020-2031)
- 5.6.3 Asia Pacific Bevacizumab Injection Revenue by Country (2020-2031)
- 5.6.4 China
- 5.6.5 Japan
- 5.6.6 South Korea
- 5.6.7 India
- 5.6.8 Australia
- 5.6.9 China Taiwan
- 5.6.10 Southeast Asia
- 5.7 South America Bevacizumab Injection Market Facts & Figures by Country
- 5.7.1 South America Bevacizumab Injection Market Size by Country: 2020 VS 2024 VS 2031
- 5.7.2 South America Bevacizumab Injection Sales by Country (2020-2031)
- 5.7.3 South America Bevacizumab Injection Revenue by Country (2020-2031)
- 5.7.4 Mexico
- 5.7.5 Brazil
- 5.7.6 Argentina
- 5.8 Middle East and Africa Bevacizumab Injection Market Facts & Figures by Country
- 5.8.1 Middle East and Africa Bevacizumab Injection Market Size by Country: 2020 VS 2024 VS 2031
- 5.8.2 Middle East and Africa Bevacizumab Injection Sales by Country (2020-2031)
- 5.8.3 Middle East and Africa Bevacizumab Injection Revenue by Country (2020-2031)
- 5.8.4 Turkey
- 5.8.5 Saudi Arabia
- 5.8.6 UAE
- 6 Segment by Type
- 6.1 Global Bevacizumab Injection Sales by Type (2020-2031)
- 6.1.1 Global Bevacizumab Injection Sales by Type (2020-2031) & (K Doses)
- 6.1.2 Global Bevacizumab Injection Sales Market Share by Type (2020-2031)
- 6.2 Global Bevacizumab Injection Revenue by Type (2020-2031)
- 6.2.1 Global Bevacizumab Injection Sales by Type (2020-2031) & (US$ Million)
- 6.2.2 Global Bevacizumab Injection Revenue Market Share by Type (2020-2031)
- 6.3 Global Bevacizumab Injection Price by Type (2020-2031)
- 7 Segment by Application
- 7.1 Global Bevacizumab Injection Sales by Application (2020-2031)
- 7.1.1 Global Bevacizumab Injection Sales by Application (2020-2031) & (K Doses)
- 7.1.2 Global Bevacizumab Injection Sales Market Share by Application (2020-2031)
- 7.2 Global Bevacizumab Injection Revenue by Application (2020-2031)
- 7.2.1 Global Bevacizumab Injection Sales by Application (2020-2031) & (US$ Million)
- 7.2.2 Global Bevacizumab Injection Revenue Market Share by Application (2020-2031)
- 7.3 Global Bevacizumab Injection Price by Application (2020-2031)
- 8 Value Chain and Sales Channels Analysis of the Market
- 8.1 Bevacizumab Injection Value Chain Analysis
- 8.1.1 Bevacizumab Injection Key Raw Materials
- 8.1.2 Raw Materials Key Suppliers
- 8.1.3 Bevacizumab Injection Production Mode & Process
- 8.2 Bevacizumab Injection Sales Channels Analysis
- 8.2.1 Direct Comparison with Distribution Share
- 8.2.2 Bevacizumab Injection Distributors
- 8.2.3 Bevacizumab Injection Customers
- 9 Global Bevacizumab Injection Analyzing Market Dynamics
- 9.1 Bevacizumab Injection Industry Trends
- 9.2 Bevacizumab Injection Industry Drivers
- 9.3 Bevacizumab Injection Industry Opportunities and Challenges
- 9.4 Bevacizumab Injection Industry Restraints
- 10 Report Conclusion
- 11 Disclaimer
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.